A Form 4 filed on August 25, 2026 discloses multiple Common Stock transactions on August 23, 2026 by Stephen W. Beard, Chairman and CEO of Covista Inc. (CVSA), reflecting the payout of performance share units and related tax withholding disposals.
Director Helen S. Santiago of Citizens & Northern Corp filed a statement of changes in beneficial ownership on August 25, 2026, reporting common stock acquisitions dated August 14, 2026, through the company's dividend reinvestment plan.
Cary M. Okawa, Chief Accounting Officer of OSI Systems Inc, filed a Form 4 on August 25, 2026, reporting a transaction in OSI Systems common stock dated August 22, 2026.
A Form 4 filed on August 25, 2026 discloses that Dana Elizabeth Wolf, a director of A10 Networks, Inc. (NYSE:ATEN), sold 2,652 shares of common stock on August 25, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.
An amended statement of changes in beneficial ownership for Citizens & Northern Corp (NASDAQ:CZNC) director Christian C. Trate was filed on August 25, 2026, amending an original filing dated August 4, 2026, and reporting a transaction dated August 3, 2026.
Leggett & Platt, Incorporated filed a current report on August 25, 2026, disclosing that all requisite regulatory approvals for its planned merger with Somnigroup International Inc. have been received, with the company anticipating closing as early as August 26, 2026.
Somnigroup International Inc. filed a Form 8-K on August 25, 2026, disclosing that it has received all requisite regulatory approvals for its planned merger with Leggett & Platt, Incorporated, and anticipates closing the transaction as early as August 26, 2026.
Realty Income Corporation filed a Form 8-K on August 25, 2026, disclosing that on August 20, 2026, the company entered into amendments to two existing term loan agreements, conforming their terms to a recently closed credit agreement.
Wolfspeed, Inc. filed a Form 8-K on August 25, 2026, disclosing that Aris Bolisay, the Renesas Electronics Corporation representative on the company's Board of Directors, will resign from the board effective September 27, 2026.
Spyre Therapeutics, Inc. filed a Form 8-K with the SEC on August 25, 2026, disclosing topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in patients with moderate to severely active RA.